cydectin pour-on vet 5 mg/ml kertavaleluliuos
zoetis animal health aps - moxidectine - kertavaleluliuos - 5 mg/ml - moksidektiini
noromectin pour-on vet 5 mg/ml kertavaleluliuos
norbrook laboratories (ireland) limited - ivermectin - kertavaleluliuos - 5 mg/ml - ivermektiini
eprinex vet. 5 mg/ml kertavaleluliuos
boehringer ingelheim animal health nordics a/s - eprinomectin - kertavaleluliuos - 5 mg/ml - eprinomektiini
adempas
bayer ag - riociguat - hypertensio, keuhkokuume - keuhkoverenpainetaudin verenpainelääkkeet - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. teho on osoitettu in pah väestöön, mukaan lukien etiologia idiopaattinen tai periytyviä pah-yhdisteiden tai pah-yhdisteiden liittyy sidekudoksen sairaus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
virbamec vet 10 mg/ml injektioneste, liuos
virbac - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
bimectin vet 10 mg/ml injektioneste, liuos
bimeda animal health limited - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
animec vet 10 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
cuprymina
a.c.o.m. - advanced center oncology - kupari (64cu) kloridi - radionuklidien kuvantaminen - various diagnostic radiopharmaceuticals - cuprymina on radiofarmaseuttinen prekursori. sitä ei ole tarkoitettu suoraan potilaille. tätä lääkevalmistetta on käytettävä vain radioaktiiviseen merkintään, joka on erityisesti kehitetty ja sallittu radiolabeloitavaksi tällä radionuklidilla.
heplisav b
dynavax gmbh - hepatiitti b-pinta-antigeeni - b-hepatiitti - rokotteet - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.